Loading
A phase 2 trial of durvalumab and tremelimumab in lung cancer, run by Georgetown University, now recruiting.
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer is a phase 2, interventional study registered as NCT04499053 by Georgetown University, with a registry enrolment figure of 18 participants, started 2020-12-09 and due to reach its primary completion in 2027-02. Interventions recorded: Durvalumab; Tremelimumab. Conditions listed: Carcinoma, Non-Small Cell Lung. Primary outcome: Adverse Events; Radiological Response. Lung eligibility wording from the registry: "Patients with stage IV NSCLC who had undergone no previous systemic therapy for stage IV disease". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Lung cancer trials open today (registry snapshot), AstraZeneca, Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Durvalumab, Lung cancer trials open today (registry snapshot), AstraZeneca, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Durvalumab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), AstraZeneca, Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Tremelimumab, Durvalumab, Lung cancer trials open today (registry snapshot), AstraZeneca and the tag lung-deep-dive.
Shares Durvalumab, Lung cancer trials open today (registry snapshot), AstraZeneca, Immune checkpoint inhibitors and the tag lung-deep-dive.